Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vistin Pharma ASA's Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr107.5 Mil. Therefore, Vistin Pharma ASA's EV-to-EBIT ratio for today is 8.27.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Vistin Pharma ASA's Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr131.0 Mil. Therefore, Vistin Pharma ASA's EV-to-EBITDA ratio for today is 6.79.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Vistin Pharma ASA's Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr449.5 Mil. Therefore, Vistin Pharma ASA's EV-to-Revenue ratio for today is 1.98.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Vistin Pharma ASA (OSL:VISTN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr107.5 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr131.0 Mil.
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr449.5 Mil.
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr68.9 Mil.
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil.
Vistin Pharma ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr51.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA Enterprise Value Related Terms
Vistin Pharma ASA Enterprise Value Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:VISTN vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Vistin Pharma ASA's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (OSL:VISTN) has a Enterprise Value of kr888.8 Mil as of Jul. 06, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Enterprise Value too high?
Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Enterprise Value compare to ZTS and UTHR?
Vistin Pharma ASA's Enterprise Value of kr888.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Enterprise Value is kr888.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (OSL:VISTN) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.40 — trading 20.3% below its estimated fair value. The current Enterprise Value is kr888.8 Mil. Vistin Pharma ASA's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Vistin Pharma ASA (OSL:VISTN), the current Enterprise Value is kr888.8 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (OSL:VISTN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.40 is trading 20.3% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for OSL:VISTN:
Enterprise Value: kr888.8 Mil
GF Value™: kr25.61 vs. price of kr20.40 (20.3% below fair value)
No single metric tells the full story. See the OSL:VISTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score
Get the complete analysis for OSL:VISTN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:VISTN has been successfully added to your 
